|
1
|
Baraniskin A, Kuhnhenn J, Schlegel U,
Maghnouj A, Zöllner H, Schmiegel W, Hahn S and Schroers R:
Identification of microRNAs in the cerebrospinal fluid as biomarker
for the diagnosis of glioma. Neuro-oncol. 14:29–33. 2012.
View Article : Google Scholar :
|
|
2
|
Gabayan AJ, Green SB, Sanan A, Jenrette J,
Schultz C, Papagikos M, Tatter SP, Patel A, Amin P, Lustig R, et
al: GliaSite brachytherapy for treatment of recurrent malignant
gliomas: A retrospective multi-institutional analysis.
Neurosurgery. 58:701–709; discussion 701–709. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rocha CR, Garcia CC, Vieira DB, Quinet A,
de Andrade-Lima LC, Munford V, Belizário JE and Menck CF:
Glutathione depletion sensitizes cisplatin- and
temozolomide-resistant glioma cells in vitro and in vivo. Cell
Death Dis. 6:e17272015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cai Y, Yu X, Hu S and Yu J: A brief review
on the mechanisms of miRNA regulation. Genomics Proteomics
Bioinformatics. 7:147–154. 2009. View Article : Google Scholar
|
|
5
|
Patnaik S, Mallick R, Kannisto E, Sharma
R, Bshara W, Yendamuri S and Dhillon SS: MiR-205 and MiR-375
microRNA assays to distinguish squamous cell carcinoma from
adenocarcinoma in lung cancer biopsies. J Thorac Oncol. 10:446–453.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khan S, Wall D, Curran C, Newell J, Kerin
MJ and Dwyer RM: MicroRNA-10a is reduced in breast cancer and
regulated in part through retinoic acid. BMC Cancer. 15:3452015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu K, Zhang C, Li T, Ding Y, Tu T, Zhou
F, Qi W, Chen H and Sun X: Let-7a inhibits growth and migration of
breast cancer cells by targeting HMGA1. Int J Oncol. 46:2526–2534.
2015.PubMed/NCBI
|
|
8
|
Wang YW, Chen X, Gao JW, Zhang H, Ma RR,
Gao ZH and Gao P: High expression of cAMP-responsive
element-binding protein 1 (CREB1) is associated with metastasis,
tumor stage and poor outcome in gastric cancer. Oncotarget.
6:10646–10657. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai NS, Wu DG, Fang XG, Lin YC, Chen SS,
Li ZB and Xu SS: Serum microRNA-210 as a potential noninvasive
biomarker for the diagnosis and prognosis of glioma. Br J Cancer.
112(Suppl): 1241–1246. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Y, Yan K, Fang J, Qu Q, Zhou M and
Chen F: Let-7b expression determines response to chemotherapy
through the regulation of cyclin D1 in glioblastoma. J Exp Clin
Cancer Res. 32:412013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Q, Wang Z, Chu L, Li X, Kan P, Xin X,
Zhu Y and Yang P: The effects and molecular mechanisms of miR-106a
in multidrug resistance reversal in human glioma U87/DDP and U251/G
cell lines. PLoS One. 10:e01254732015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen W, Yang Y, Chen B, Lu P, Zhan L, Yu
Q, Cao K and Li Q: MiR-136 targets E2F1 to reverse cisplatin
chemosensitivity in glioma cells. J Neurooncol. 120:43–53. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Y, Wu J, Guan H, Cai J, Fang L, Li J
and Li M: MiR-136 promotes apoptosis of glioma cells by targeting
AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui J, Bi M, Overstreet AM, Yang Y, Li H,
Leng Y, Qian K, Huang Q, Zhang C, Lu Z, et al: MiR-873 regulates
Erα transcriptional activity and tamoxifen resistance via targeting
CDK3 in breast cancer cells. Oncogene. 22–Dec;2014.(Epub ahead of
print). View Article : Google Scholar
|
|
16
|
Liu X, He F, Pang R, Zhao D, Qiu W, Shan
K, Zhang J, Lu Y, Li Y and Wang Y: Interleukin-17 (IL-17)-induced
microRNA 873 (miR-873) contributes to the pathogenesis of
experimental autoimmune encephalomyelitis by targeting A20
ubiquitin-editing enzyme. J Biol Chem. 289:28971–28986. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Skalsky RL and Cullen BR: Reduced
expression of brain-enriched microRNAs in glioblastomas permits
targeted regulation of a cell death gene. PLoS One. 6:e242482011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y,
Wang HB, Wen JQ, Liu X, Li XF, Sun Y, et al: MiR-139 inhibits Mcl-1
expression and potentiates TMZ-induced apoptosis in glioma. CNS
Neurosci Ther. 19:477–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lynam-Lennon N, Maher SG and Reynolds JV:
The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos
Soc. 84:55–71. 2009. View Article : Google Scholar
|
|
20
|
Koufaris C, Papagregoriou G, Kousoulidou
L, Moutafi M, Tauber M, Jouret B, Kieffer I, Deltas C, Tanteles GA,
Anastasiadou V, et al: Haploinsufficiency of the miR-873/miR-876
microRNA cluster is associated with craniofacial abnormalities.
Gene. 561:95–100. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wick W, Wagner S, Kerkau S, Dichgans J,
Tonn JC and Weller M: BCL-2 promotes migration and invasiveness of
human glioma cells. FEBS Lett. 440:419–424. 1998. View Article : Google Scholar
|
|
22
|
Wick W, Wild-Bode C, Frank B and Weller M:
BCL-2-induced glioma cell invasiveness depends on furin-like
proteases. J Neurochem. 91:1275–1283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu CJ, Li YB and Wong MC: Expression of
antisense bcl-2 cDNA abolishes tumorigenicity and enhances
chemosensitivity of human malignant glioma cells. J Neurosci Res.
74:60–66. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang F, Li T, Zhang B, Li H, Wu Q, Yang L,
Nie Y, Wu K, Shi Y and Fan D: MicroRNA-19a/b regulates multidrug
resistance in human gastric cancer cells by targeting PTEN. Biochem
Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar
|
